RM-TRS / Tissue, repair and matrix signalling
TB-500
Also known as: Thymosin beta-4 fragment
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
A peptide marketed under a trade-style name and related to thymosin beta-4. The published human work concerns topical full-length thymosin beta-4, not this fragment or route.
Evidence position
Grade D. Related-compound evidence only. Exact sequence, molecular mass, salt and reference standard are required before identity can be asserted.
What the record does not establish
Published research about a molecule is not a test of any particular vial. Identity, purity, strength and microbiological quality are established by lot-level analytical records tied to a matched sample — not by the literature, and not by the presence of an approved comparator.
Where a lot-level record exists it is published on the evidence page and linked from the product. Where it does not exist, the record says so.
Sources
- 01Phase 2 topical thymosin beta-4 venous ulcer studyPubMed
- Shows
- Human data for topical full-length thymosin beta-4
- Does not show
- Different material, different route
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Unii-qhk6Z47gtg
- CID
- 62707662
- Formula
- C38H68N10O14
- Mass
- 889.0
PUBMED / FOUND RECORDS
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews / 2026 Jan 1PMID 41490200 / DOI 10.5435/JAAOSGlobal-D-25-00236
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.The American journal of sports medicine / 2026 JanPMID 41476424 / DOI 10.1177/03635465251357593
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports medicine (Auckland, N.Z.) / 2026 Apr 12PMID 41966639 / DOI 10.1007/s40279-026-02437-0
- Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences / 2024 Mar 1PMID 38382158 / DOI 10.1016/j.jchromb.2024.124033
- Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.Frontiers in aging / 2026PMID 42021992 / DOI 10.3389/fragi.2026.1790247
CLINICALTRIALS.GOV / FOUND RECORDS
- TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVDRECRUITING / PHASE1, PHASE2 / Hudson BiotechNCT07487363 / DIRECT intervention MATCH: TB-500